About This Deal

Danaher Corporation acquired Abcam plc for approximately $5.6 billion cash purchase price ($24.00 per share), a transaction completed in December 2023, structured as all cash.

Abcam plc operates in Life Sciences (protein consumables), is based in Cambridge, United Kingdom. Danaher acquired Abcam plc in December 2023 for ~$5.6 billion; Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays addressing targets in biological pathways.

Added to Danaher's Life Sciences segment, providing additional sales and earnings opportunities in the proteomics sector.

Deal Terms

Acquirer
Danaher Corporation
Target
Abcam plc
Value
Approximately $5.6 billion cash purchase price ($24.00 per share)
Date
December 2023
Type
Full acquisition
Status
Ready

Transaction Details

Target HQ
Cambridge, United Kingdom
Segment
Life Sciences (protein consumables)
Structure
All cash
Announced
August 1, 2023
Closed
December 6, 2023

In Their Words

On December 6, 2023, the Company acquired Abcam plc (“Abcam”) for a cash purchase price of approximately $5.6 billion (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways.Danaher Corporation FY23 10-K, acquisition note

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗ · Last updated July 8, 2026

See how VectorShift works for your firm

Request Demo